Clinical trials: Tocilizumab
Rheumatoid Arthritis
A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis
This extension study of WA19926 will assess the long-term safety and the efficacy of RoActemra/Actemra (tocilizumab) treatment in participants with rheumatoid arthritis.
- Trial name
- NCT01649804
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 3 sites in Hungary
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Healthy Subjects
A Study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects
A study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects
- Trial name
- NCT05188378
- Testing
- CT-P47, EU-approved RoActemra,
- Where
- South Korea
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Celltrion
Rheumatoid Arthritis
A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis
This multi-center observational study will evaluate the use and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to severe rheumatoid arthritis.
- Trial name
- NCT01670045
- Testing
- Tocilizumab
- Where
- 9 sites in Indonesia
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Healthy
Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456
This study aims to compare the PK/PD of a single injection of investigational Medicinal Product (IMP) MSB11456, US licensed Actemra and EU approved RoActemra in healthy adult subjects.
- Trial name
- NCT03282851
- Testing
- MSB11456, US-licensed Actemra, EU-approved RoActemra
- Where
- 2 sites in New Zealand
- Volunteers
- 696 people, healthy volunteers welcome
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Rheumatoid Arthritis
An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
This prospective, observational, multicenter study will assess the efficacy and safety of RoActemra/Actemra (tocilizumab) on the use of glucocorticoids in patients with moderate to severe rheumatoid arthritis and an inadequate…
- Trial name
- NCT01564901
- Where
- 13 sites in Spain
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Juvenile Idiopathic Arthritis
A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)
This is a multi-center, open-label single-arm study to investigate the pharmacokinetics and safety of tocilizumab (RoActemra/Actemra) in participants less than 2 years old with active sJIA.
- Trial name
- NCT01455701
- Testing
- Tocilizumab
- Where
- 20 sites in United States, Argentina and 6 more
- Volunteers
- 11 people
- Sponsor
- Hoffmann-La Roche
Juvenile Idiopathic Arthritis
A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)
This open-label, multicenter study evaluated the pharmacokinetics, pharmacodynamics and safety of SC administered TCZ in participants with pJIA.
- Trial name
- JIGSAW 117 (NCT01904279)
- Testing
- Tocilizumab
- Where
- 35 sites in United States, Argentina and 10 more
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
An Observational Study of the Impact of RoActemra/Actemra on Fatigue in Patients With Rheumatoid Arthritis (PEPS)
This prospective, observational study will assess the effect of RoActemra/Actemra (tocilizumab) on fatigue in patients with moderate to severe rheumatoid arthritis who have an inadequate response to disease-modifying…
- Trial name
- NCT01185522
- Where
- France
- Volunteers
- 719 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis
This single arm, open-label study will assess the safety and efficacy with regar d to reduction of signs and symptoms of treatment with tocilizumab in combinatio n with methotrexate, in patients with moderate to severe active…
- Trial name
- NCT00754572
- Testing
- tocilizumab [RoActemra/Actemra], methotrexate
- Where
- 69 sites in Argentina, Brazil and 8 more
- Volunteers
- 418 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)
This observational study will evaluate the safety and efficacy of tocilizumab in participants with active moderate to severe RA and an inadequate response to non-biologic DMARDs.
- Trial name
- NCT01617005
- Testing
- Tocilizumab
- Where
- Montenegro
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
The Durability of Early RA Disease Control After Tocilizumab Withdrawal: A Canadian Experience
Patients who participated in the FUNCTION Study (Protocol WA19926) will be enrolled in this study. The investigators want to learn how long it takes Early Rheumatoid Arthritis patients who were treated with Tocilizumab to require…
- Trial name
- NCT03109470
- Sponsor
- Pope Research Corporation
Rheumatoid Arthritis
An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
This observational, prospective, open-label, multi-center study will evaluate the effectiveness in disease reduction and the safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis.
- Trial name
- NCT01277328
- Where
- Romania
- Volunteers
- 95 people
- Sponsor
- Hoffmann-La Roche
COVID-19 Pneumonia
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia
This study will assess the pharmacodynamics, pharmacokinetics, safety and efficacy of two different doses of tocilizumab (TCZ) in combination with standard-of-care (SOC) in hospitalized adult participants with moderate to severe…
- Trial name
- MARIPOSA (NCT04363736)
- Testing
- Tociliuzumab
- Where
- 24 sites in United States
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis
This is a phase 3 study to compare efficacy and safety of CT-P47 and RoActemra in patients with moderate to severe active rheumatoid arthritis.
- Trial name
- NCT05489224
- Testing
- CT-P47, EU-approved RoActemra
- Where
- Poland
- Volunteers
- 471 people
- Sponsor
- Celltrion
Rheumatoid Arthritis
A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis
This Phase IIIb, multicenter, open label, single arm study will evaluate the safety and efficacy of subcutaneous (SC) tocilizumab as monotherapy or in combination with methotrexate or other non-biologic DMARDs in participants…
- Trial name
- NCT01941095
- Testing
- Azathioprine, Chloroquine, Hydroxychloroquine
- Where
- 10 sites in Greece
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of Tocilizumab in Patients With Rheumatoid Arthritis
This is an open-label, uncontrolled, observational study in patients with rheumatoid arthritis (RA) who are receiving tocilizumab concomitantly with methotrexate as part of their standard of care.
- Trial name
- NCT01187563
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Regeneron Pharmaceuticals
Rheumatoid Arthritis
A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)
This open-label extension study will evaluate the long-term safety and efficacy of SC TCZ in participants with moderate to severe RA who have completed the 97-week WA22762 (NCT01194414) or 96-week NA25220 (NCT01232569) core…
- Trial name
- NCT01662063
- Testing
- Tocilizumab
- Where
- 79 sites in United States, Puerto Rico
- Volunteers
- 218 people
- Sponsor
- Genentech, Inc.
Juvenile Idiopathic Arthritis
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study
This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who completed the WA19977 core study.
- Trial name
- NCT01667471
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 3 sites in Germany
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of CDP6038 treatment in adult subjects with active rheumatoid arthritis who have had an inadequate response to anti-tumor…
- Trial name
- NCT01242488
- Testing
- CDP6038, Tocilizumab (Actemra or RoActemra)
- Where
- 82 sites in United States, Belgium and 1 more
- Volunteers
- 221 people
- Sponsor
- UCB Pharma
Rheumatoid Arthritis
An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.
This open-label, single arm study will investigate the safety, tolerability and efficacy of tocilizumab monotherapy, or combination therapy with non-biologic disease modifying antirheumatic drugs (DMARDs), in patients with severe…
- Trial name
- NCT00750880
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 282 sites in Australia, Austria and 23 more
- Volunteers
- 1,681 people
- Sponsor
- Hoffmann-La Roche